Pushing Boundaries in HER2 Therapy: The ENHERTU Revolution

adicionou um novo artigo Health

2025-07-28 11:25:03

ENHERTU (fam-trastuzumab deruxtecan) has emerged as a groundbreaking force in oncological therapeutics, fundamentally altering treatment landscapes for HER2-positive cancers. This cutting-edge antibody-drug conjugate, developed through collaborative innovation between Daiichi Sankyo and AstraZeneca, has achieved remarkable regulatory success with approvals encompassing breast cancer, gastric...

0 Comentários 0 Compartilhamentos 104 Visualizações 0 Anterior